The important clinical trials demonstrated the important benefits of SGLT2 inhibitors, without any side effect, including lower rate of the primary composite cardiovascular outcome [10, 36] as well as achievement of superior diabetes-control and blood pressure, at least, related with the early stages of vascular remodelling [32]. Here, SLC5A2 is linked to diabetes mellitus.